WO2005007072A3 - Methods and pharmaceutical compositions for healing wounds - Google Patents

Methods and pharmaceutical compositions for healing wounds Download PDF

Info

Publication number
WO2005007072A3
WO2005007072A3 PCT/IL2004/000640 IL2004000640W WO2005007072A3 WO 2005007072 A3 WO2005007072 A3 WO 2005007072A3 IL 2004000640 W IL2004000640 W IL 2004000640W WO 2005007072 A3 WO2005007072 A3 WO 2005007072A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
insulin
pharmaceutical composition
methods
healing process
Prior art date
Application number
PCT/IL2004/000640
Other languages
French (fr)
Other versions
WO2005007072A2 (en
Inventor
Tamar Tennenbaum
Sanford Sampson
Toshio Kuroki
Addy Alt
Shlomzion Shen
Original Assignee
Univ Bar Ilan
Tamar Tennenbaum
Sanford Sampson
Toshio Kuroki
Addy Alt
Shlomzion Shen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ545318A priority Critical patent/NZ545318A/en
Priority to AU2004257485A priority patent/AU2004257485B2/en
Priority to JP2006520104A priority patent/JP4790609B2/en
Priority to CN2004800265295A priority patent/CN1852722B/en
Priority to EP04744980.6A priority patent/EP1648474B1/en
Priority to CA002532352A priority patent/CA2532352A1/en
Application filed by Univ Bar Ilan, Tamar Tennenbaum, Sanford Sampson, Toshio Kuroki, Addy Alt, Shlomzion Shen filed Critical Univ Bar Ilan
Publication of WO2005007072A2 publication Critical patent/WO2005007072A2/en
Publication of WO2005007072A3 publication Critical patent/WO2005007072A3/en
Priority to IL173148A priority patent/IL173148A/en
Priority to US11/332,774 priority patent/US20060258562A1/en
Priority to HK06111616.5A priority patent/HK1090843A1/en
Priority to IL221624A priority patent/IL221624A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

A pharmaceutical composition for inducing or accelerating a healing process of a damaged skin or skin wound, the pharmaceutical composition comprises, as an active ingredient, a therapeutically effective amount of insulin and at least one additional agent acting in synergy with said insulin, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition. A method of inducing or accelerating a healing process of a damaged skin or skin wound, the method comprises administering to the damaged skin or skin wound a therapeutically effective amount of insulin and at least one additional agent acting in synergy with said insulin to induce or accelerate the healing process of the damaged skin or the skin wound.
PCT/IL2004/000640 2000-07-31 2004-07-15 Methods and pharmaceutical compositions for healing wounds WO2005007072A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2004257485A AU2004257485B2 (en) 2003-07-15 2004-07-15 Methods and pharmaceutical compositions for healing wounds
JP2006520104A JP4790609B2 (en) 2003-07-15 2004-07-15 Methods and pharmaceutical compositions for wound healing
CN2004800265295A CN1852722B (en) 2003-07-15 2004-07-15 Use of insulin and myristoylation PKC alpha Pseudo substrate in preparing medicine for healing skin wound
EP04744980.6A EP1648474B1 (en) 2003-07-15 2004-07-15 Pharmaceutical compositions for healing wounds
CA002532352A CA2532352A1 (en) 2003-07-15 2004-07-15 Methods and pharmaceutical compositions for healing wounds
NZ545318A NZ545318A (en) 2003-07-15 2004-07-15 Pharmaceutical compositions for healing wounds comprising insulin and PKC alpha inhibitor
IL173148A IL173148A (en) 2003-07-15 2006-01-15 Use of insulin for the preparation of pharmaceutical compositions for healing wounds
US11/332,774 US20060258562A1 (en) 2000-07-31 2006-01-17 Methods and pharmaceutical compositions for healing wounds
HK06111616.5A HK1090843A1 (en) 2003-07-15 2006-10-20 Pharmaceutical compositions for healing wounds
IL221624A IL221624A0 (en) 2003-07-15 2012-08-23 Methods and pharmaceutical compositions for healing wounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48690603P 2003-07-15 2003-07-15
US60/486,906 2003-07-15
US10/644,775 2003-08-21
US10/644,775 US20040037828A1 (en) 2002-07-09 2003-08-21 Methods and pharmaceutical compositions for healing wounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/332,774 Continuation-In-Part US20060258562A1 (en) 2000-07-31 2006-01-17 Methods and pharmaceutical compositions for healing wounds

Publications (2)

Publication Number Publication Date
WO2005007072A2 WO2005007072A2 (en) 2005-01-27
WO2005007072A3 true WO2005007072A3 (en) 2005-05-12

Family

ID=34083396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2004/000640 WO2005007072A2 (en) 2000-07-31 2004-07-15 Methods and pharmaceutical compositions for healing wounds

Country Status (9)

Country Link
US (4) US20040037828A1 (en)
EP (5) EP2526952A1 (en)
JP (1) JP5852051B2 (en)
CN (1) CN103751211A (en)
AU (2) AU2004257485B2 (en)
CA (1) CA2532352A1 (en)
HK (1) HK1090843A1 (en)
RU (2) RU2359694C2 (en)
WO (1) WO2005007072A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8436401A (en) 2000-07-31 2002-02-13 Univ Bar Ilan Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20050129776A1 (en) * 2002-05-03 2005-06-16 Inserm Microparticles supporting cells and active substances
RU2358753C2 (en) * 2003-08-07 2009-06-20 Хилор Лтд. Pharmaceutical compositions and wound healing acceleration techniques
ZA200802546B (en) 2005-08-29 2009-10-28 Healor Ltd Methods and compositions for prvention and treatment of diabetic and aged skin
WO2007131047A2 (en) * 2006-05-02 2007-11-15 University Of Miami Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
NZ582556A (en) * 2007-07-30 2013-02-22 Healor Ltd Pharmaceutical composition for treating wounds and related methods
WO2009108890A1 (en) 2008-02-27 2009-09-03 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
CA2786854A1 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
WO2012070967A1 (en) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Wound-healing, burn-treating, regenerative and antiviral pharmaceutical composition for topical application
US10292997B2 (en) 2011-01-17 2019-05-21 Daniel N. Rastein Compositions and methods for stimulating wound healing
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en) * 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
EP3011959A1 (en) 2014-10-23 2016-04-27 Santen SAS Quaternary ammonium compound for use as an inhibitor of protein kinase C alpha
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US20180256537A1 (en) * 2015-09-23 2018-09-13 Tapan K. Khan Methods for survival and rejuvenation of dermal fibroblasts using pkc activators
EP3538132B1 (en) 2016-11-14 2020-12-30 University of Copenhagen Rectal insulin for treatment of inflammatory bowel diseases
AU2018269377A1 (en) 2017-05-17 2019-12-19 Berg Llc Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa
CA3079544A1 (en) 2017-10-19 2019-04-25 Mona E. Buice Topical composition for improved healing of open wounds
CN114323894A (en) * 2021-12-20 2022-04-12 南京美新诺医药科技有限公司 Method for analyzing medicine in tissue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009639A2 (en) * 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
US6737241B2 (en) * 1996-01-23 2004-05-18 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1447701A (en) 1919-10-02 1923-03-06 Anchor Cap & Closure Corp Apparatus for indicating pressure conditions in sealed containers
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4558033A (en) * 1983-06-06 1985-12-10 Amgen Potentiation of the effects of insulin by peptides
US4673649A (en) * 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
EP0178321A1 (en) 1984-04-30 1986-04-23 The Trustees Of Columbia University In The City Of New York Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE3674883D1 (en) * 1985-11-25 1990-11-15 Wako Pure Chem Ind Ltd COLOR DEVELOPMENT METHOD IN CLINICAL EXAMINATIONS.
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
JPH0739508B2 (en) * 1986-11-11 1995-05-01 株式会社林原生物化学研究所 Pullulan / polyethylene glycol aggregate, its production method and use
US4885163A (en) 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
ATE132266T1 (en) 1987-05-01 1996-01-15 Stratagene Inc MUTAGENEOSIS TESTING USING NON-HUMAN LIVING BEINGS CONTAINING TEST DNA SEQUENCES
JPS63303929A (en) 1987-06-04 1988-12-12 Kanji Izumi Wound treating agent
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US5700450A (en) 1988-03-30 1997-12-23 The Trustees Of Boston University Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof
ZA892928B (en) 1988-04-25 1991-01-30 Pro Neuron Inc Pharmaceutical compositions containing deoxyribonucleosides for wound healing
US5221778A (en) 1988-08-24 1993-06-22 Yale University Multiplex gene regulation
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5137734A (en) * 1989-03-22 1992-08-11 Dana Farber Cancer Institute Angiogenic monoglycerides
US5158935A (en) * 1989-05-12 1992-10-27 Chiron Corporation Human epidermal growth factor having substitution at position 11
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
US5423778A (en) 1989-12-14 1995-06-13 Elof Eriksson System and method for transplantation of cells
CA2085127C (en) 1990-06-15 2002-12-10 Barbara Cordell Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5288846A (en) 1990-10-19 1994-02-22 The General Hospital Corporation Cell specific gene regulators
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
EP0508792A1 (en) 1991-04-11 1992-10-14 Schering Corporation Anti-tumor and anti-psoriatic agents
DK0580778T3 (en) * 1991-04-19 2000-01-31 Lds Technologies Inc Convertible microemulsion formulations
JPH0543453A (en) 1991-08-20 1993-02-23 Sumitomo Pharmaceut Co Ltd Local sustained-release preparation for accelerating wound curing
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
WO1993008825A1 (en) * 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
PT620849E (en) 1992-01-07 2003-11-28 Elan Pharm Inc TRANSGENIC ANIMAL MODELS FOR ALZHEIMER'S DISEASE
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
DE4208552A1 (en) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh TOPICAL MEDICINE FORMS WITH INSULIN
GB9210574D0 (en) 1992-05-18 1992-07-01 Ca Nat Research Council Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
WO1994023049A2 (en) 1993-04-02 1994-10-13 The Johns Hopkins University The introduction and expression of large genomic sequences in transgenic animals
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
US6485721B1 (en) * 1994-04-25 2002-11-26 Research Development Corporation Of Japan Biologically active substance-secreting hybrid gel
US6028118A (en) * 1996-08-08 2000-02-22 Les Laboratoires Aeterna Inc. Methods of using extracts of shark cartilage
RU2198900C2 (en) 1994-05-24 2003-02-20 Еда Рисерч энд Дивелопмент Ко., Лтд. Improved copolymer-1 and method of preparation thereof
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
JPH07316066A (en) 1994-05-26 1995-12-05 Mochida Pharmaceut Co Ltd Wound healing agent
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
CZ290079B6 (en) 1994-12-29 2002-05-15 Bio-Technology General Corp. Process for preparing insulin and intermediate for this process
AUPN089295A0 (en) 1995-02-02 1995-03-02 International Diabetes Institute Treatment of diabetic neuropathy
US5631245A (en) * 1995-06-06 1997-05-20 Biodynamics Pharmaceuticals, Inc. Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions
GB2310955A (en) 1996-03-06 1997-09-10 Central Research Lab Ltd Apparatus for blocking a dc component of a signal
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
JPH10158188A (en) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd Composition for treating cornea
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
JPH10265405A (en) 1997-03-19 1998-10-06 Masaaki Nanbara Skin preparation containing insulin for external use
EP1051142A4 (en) 1997-10-16 2002-01-30 Deguang Zhu A new powerful cosmetic or pharmaceutical composition
AU3635099A (en) * 1997-12-15 1999-07-26 Beth Israel Deaconess Medical Center Methods and reagents for modulating cell motility
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
FR2773075B1 (en) * 1997-12-31 2000-05-05 Cird Galderma USE OF PPAR-GAMMA ACTIVATORS IN DERMATOLOGY
WO1999034821A1 (en) 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6790207B2 (en) * 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6489306B2 (en) * 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
AU760664B2 (en) 1998-04-17 2003-05-22 Angiogenix, Inc. Therapeutic angiogenic factors and methods for their use
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
EP1098902A4 (en) * 1998-07-23 2002-07-24 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
HU229720B1 (en) * 1998-09-25 2014-05-28 Yeda Res & Dev Copolymer 1 related polypeptides for us as molecular weight markers and for therapeutic use
US6096288A (en) * 1998-10-12 2000-08-01 Mobil Oil Corporation Synthesis of the cubic mesoporous molecular sieve MCM-48
CA2350599A1 (en) 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US7261881B1 (en) * 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6541447B1 (en) * 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
AU2001247219B2 (en) * 2000-02-25 2007-01-04 Immunex Corporation Integrin antagonists
AU2001251136A1 (en) 2000-04-06 2001-10-23 University Technology Corporation Compositions and methods for promoting wound healing
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US6673603B2 (en) 2000-09-01 2004-01-06 Modex Therapeutiques, S.A. Cell paste comprising keratinocytes and fibroblasts
GB2369572A (en) * 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
US20020119914A1 (en) * 2000-12-26 2002-08-29 Deguang Zhu New uses of insulin and pancreatin
JP2002198443A (en) * 2000-12-26 2002-07-12 Nec Corp Semiconductor device and its fabricating method
DK1365762T3 (en) 2001-03-08 2008-11-17 Univ Kentucky Res Found Process for increasing leptin levels using nicotinic acid compounds
JP2002272831A (en) 2001-03-14 2002-09-24 Fumio Kamiyama Wound coating tacky adhesive sheet
US20040152746A1 (en) 2001-04-30 2004-08-05 Bardsley Hazel Judith Treatment of scarring and related conditions using ppar-gamma activators
WO2002094877A2 (en) 2001-05-23 2002-11-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) New nuclear receptor cofactors and related modulators
WO2003059396A1 (en) * 2002-01-11 2003-07-24 Sergei Zolotukhin Adiponectin gene therapy
US7235062B2 (en) 2002-01-24 2007-06-26 Applied Medical Resources Corporation Surgical access device with floating gel seal
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
NZ573737A (en) * 2003-07-15 2011-06-30 Univ Bar Ilan Methods and pharmaceutical compositions for healing wounds comprising a PKC modulator
RU2358753C2 (en) 2003-08-07 2009-06-20 Хилор Лтд. Pharmaceutical compositions and wound healing acceleration techniques
US7346787B2 (en) * 2004-12-07 2008-03-18 Intel Corporation System and method for adaptive power management
US7571295B2 (en) * 2005-08-04 2009-08-04 Intel Corporation Memory manager for heterogeneous memory control
ZA200802546B (en) 2005-08-29 2009-10-28 Healor Ltd Methods and compositions for prvention and treatment of diabetic and aged skin
US20090306045A1 (en) 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
US9203086B2 (en) 2013-05-24 2015-12-01 The Boeing Company Thermally managed battery assembly
JP6149841B2 (en) 2014-10-22 2017-06-21 トヨタ自動車株式会社 Hybrid car

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737241B2 (en) * 1996-01-23 2004-05-18 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules
WO2002009639A2 (en) * 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds

Also Published As

Publication number Publication date
JP5852051B2 (en) 2016-02-03
EP1648474B1 (en) 2013-09-04
WO2005007072A2 (en) 2005-01-27
CA2532352A1 (en) 2005-01-27
US8093211B2 (en) 2012-01-10
CN103751211A (en) 2014-04-30
EP2540302A1 (en) 2013-01-02
HK1090843A1 (en) 2007-01-05
EP2526952A1 (en) 2012-11-28
US20120076764A1 (en) 2012-03-29
AU2009225335B2 (en) 2011-08-25
AU2009225335A1 (en) 2009-11-05
RU2392959C1 (en) 2010-06-27
US20090192074A1 (en) 2009-07-30
EP1648474A4 (en) 2009-03-25
EP2540301A2 (en) 2013-01-02
RU2006104617A (en) 2007-09-10
EP2526953A1 (en) 2012-11-28
AU2004257485A1 (en) 2005-01-27
US20040037828A1 (en) 2004-02-26
RU2359694C2 (en) 2009-06-27
AU2004257485B2 (en) 2010-07-01
US20080280816A1 (en) 2008-11-13
EP1648474A2 (en) 2006-04-26
JP2013177436A (en) 2013-09-09
US20100167987A9 (en) 2010-07-01
RU2008138474A (en) 2010-04-10
EP2540301A3 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
WO2001030336A3 (en) Pharmaceutical formulations comprising resveratrol and use thereof
WO2002096435A3 (en) Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
TW200616650A (en) Semi-solid delivery vehicle and pharmaceutical compositions
MXPA02002895A (en) Topical treatment of streptococcal infections.
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
WO2005034883A3 (en) A method of healing skin wounds in mammals and a composition therefor
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2005013885A3 (en) Pharmaceutical compositions and methods for accelerating wound healing
WO2007002831A3 (en) Topical skin treating compostions
WO2007098479A3 (en) Localized insulin delivery for bone healing
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2006083780A3 (en) Glucuronidated nebivolol
WO2002009639A3 (en) Methods and pharmaceutical compositions for healing wounds
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2002030467A3 (en) Pharmaceutical composition containing honey for the treatment of wounds
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
WO1999026589A3 (en) Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation
AU2002227052A1 (en) Treatments for neurogenetic disorders, impulse control disorders, and wound healing
DK1280558T3 (en) Semi-solid administration vehicle and pharmaceutical compositions
BR0007452A (en) Use of melagatran or a pharmaceutically acceptable derivative or prodrug thereof, method of treating inflammation, and, pharmaceutical formulation for use in treating inflammation
CA2519789A1 (en) Aplidine for multiple myeloma treatment

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480026529.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006/00235

Country of ref document: ZA

Ref document number: 200600235

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2532352

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006520104

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11332774

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004257485

Country of ref document: AU

Ref document number: 715/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004744980

Country of ref document: EP

Ref document number: 545318

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006104617

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2004257485

Country of ref document: AU

Date of ref document: 20040715

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004257485

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004744980

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11332774

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 221624

Country of ref document: IL